Cancer Trials Ireland
87
10
23
42
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
20.7%
18 terminated/withdrawn out of 87 trials
70.0%
-16.5% vs industry average
16%
14 trials in Phase 3/4
2%
1 of 42 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (87)
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
Role: collaborator
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
Role: collaborator
INSPIRE: INnovative SABR for Prostate Cancer All IREland
Role: lead
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
Role: collaborator
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer
Role: collaborator
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
Role: collaborator
A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17
Role: lead
The Impact of the Gene Recurrence Score on Chemotherapy Prescribing in ER Positive, Lymph Node Positive Early Stage Breast Cancer
Role: lead
PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer
Role: lead
INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer
Role: lead
Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)
Role: lead
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study
Role: lead
Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
Role: lead
Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer
Role: lead
CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
Role: lead
ANGIOPREDICT. ICORG 12-16, V3
Role: lead
Neo-adjuvant Abiraterone Prostate Study
Role: lead
Radium-223 in Combination With Enzalutamide
Role: lead
Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06
Role: lead
Identification of New Patient Stratification Tools in MSS RAS mt mCRC
Role: lead